Orgenesis (ORGS) Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services Nov 7, 2022 08:32AM
Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services Nov 7, 2022 08:30AM
Orgenesis CEO Vered Caplan to Present at William Blair’s Biotech Focus Day Series: Cell and Gene Therapy Manufacturing Dec 12, 2018 01:47PM